Baseline characteristics of the study cohort and according to LCEs
| Baseline characteristics . | Patients with LCE n = 45 . | No LCE n = 955 . | P value . |
|---|---|---|---|
| Age, y, median at transplant (IQR) | 58 (51-63) | 54 (43-62) | |
| >50 | 37 (82.2) | 507 (59.3) | .002 |
| Sex | |||
| Male | 27 (60.0) | 437 (51.1) | .245 |
| Female | 18 (40.0) | 418 (48.9) | |
| Relevant comorbidities | |||
| Active smoker at transplant | 7 (15.6) | 85 (9.9) | .381 |
| HTN | 15 (33.3) | 147 (17.2) | .005 |
| DLP | 13 (28.9) | 96 (11.2) | <.001 |
| Diabetes mellitus | 6 (13.3) | 56 (6.5) | .082 |
| Obesity (BMI ≥30) | 10 (22.2) | 50 (5.8) | <.001 |
| History of cardiac disease | 13 (28.9) | 97 (11.3) | .001 |
| Arrhythmia | 3 (6.7) | 24 (2.5) | |
| Heart failure | 4 (8.9) | 11 (1.1) | |
| Myocardial ischemia | 1 (2.2) | 1 (0.1) | |
| Pericardial disorders∗ | 2 (4.4) | 5 (0.5) | |
| Valvopathy | 2 (4.4) | 26 (2.7)) | |
| Other | 0 | 7 (0.7) | |
| Abnormalities on ECHO or ECG before allo-HCT† | 1 (2.2) | 11 (1.1) | |
| Prior treatment with cardiotoxic chemotherapy | 2 (4.4) | 24 (2.8) | .381 |
| Disease status before allo-HCT | |||
| Complete remission | 44 (97.8) | 782 (91.5) | 1 |
| Refractory AML/active disease | 1 (2.2) | 73 (8.5) | |
| HCT-CI | |||
| >3 | 4 (8.9) | 115 (13.5) | .267 |
| Intensity | |||
| Myeloablative | 23 (51.1) | 513 (60.0) | .236 |
| Reduced intensity | 22 (48.9) | 342 (40.0) | |
| MAC regimen containing CY | 3 (6.7) | 124 (14.5) | .141 |
| TBI | |||
| High dose TBI (12 Gy) | 1 (2.2) | 41 (4.8) | .366 |
| GVHD prophylaxis | |||
| PTCY-based | 21 (46.7) | 369 (43.2) | .643 |
| Others | 24 (53.3) | 486 (56.8) | |
| Donor | |||
| 10/10 MSD | 16 (35.6) | 311 (36.4) | .189 |
| 10/10 MUD | 12 (26.7) | 258 (30.2) | |
| 9/10 MMUD | 1 (2.2) | 79 (9.2) | |
| Haploidentical | 16 (35.6) | 207 (24.2) | |
| Cumulative incidence of GVHD | |||
| 2-y moderate/severe cGVHD | 14.0 (5.6-26.2) | 6.2 (4.6-8.0) | .089 |
| Relapse | 5 (11.1) | 259 (30.3) | .798 |
| Dead | 15 (33.3) | 301 (35.2) | .006 |
| Death due to NRM | 10 (22.2) | 105 (12.3) | .001 |
| Directly secondary to LCE | 2 (4.4) | N/A |
| Baseline characteristics . | Patients with LCE n = 45 . | No LCE n = 955 . | P value . |
|---|---|---|---|
| Age, y, median at transplant (IQR) | 58 (51-63) | 54 (43-62) | |
| >50 | 37 (82.2) | 507 (59.3) | .002 |
| Sex | |||
| Male | 27 (60.0) | 437 (51.1) | .245 |
| Female | 18 (40.0) | 418 (48.9) | |
| Relevant comorbidities | |||
| Active smoker at transplant | 7 (15.6) | 85 (9.9) | .381 |
| HTN | 15 (33.3) | 147 (17.2) | .005 |
| DLP | 13 (28.9) | 96 (11.2) | <.001 |
| Diabetes mellitus | 6 (13.3) | 56 (6.5) | .082 |
| Obesity (BMI ≥30) | 10 (22.2) | 50 (5.8) | <.001 |
| History of cardiac disease | 13 (28.9) | 97 (11.3) | .001 |
| Arrhythmia | 3 (6.7) | 24 (2.5) | |
| Heart failure | 4 (8.9) | 11 (1.1) | |
| Myocardial ischemia | 1 (2.2) | 1 (0.1) | |
| Pericardial disorders∗ | 2 (4.4) | 5 (0.5) | |
| Valvopathy | 2 (4.4) | 26 (2.7)) | |
| Other | 0 | 7 (0.7) | |
| Abnormalities on ECHO or ECG before allo-HCT† | 1 (2.2) | 11 (1.1) | |
| Prior treatment with cardiotoxic chemotherapy | 2 (4.4) | 24 (2.8) | .381 |
| Disease status before allo-HCT | |||
| Complete remission | 44 (97.8) | 782 (91.5) | 1 |
| Refractory AML/active disease | 1 (2.2) | 73 (8.5) | |
| HCT-CI | |||
| >3 | 4 (8.9) | 115 (13.5) | .267 |
| Intensity | |||
| Myeloablative | 23 (51.1) | 513 (60.0) | .236 |
| Reduced intensity | 22 (48.9) | 342 (40.0) | |
| MAC regimen containing CY | 3 (6.7) | 124 (14.5) | .141 |
| TBI | |||
| High dose TBI (12 Gy) | 1 (2.2) | 41 (4.8) | .366 |
| GVHD prophylaxis | |||
| PTCY-based | 21 (46.7) | 369 (43.2) | .643 |
| Others | 24 (53.3) | 486 (56.8) | |
| Donor | |||
| 10/10 MSD | 16 (35.6) | 311 (36.4) | .189 |
| 10/10 MUD | 12 (26.7) | 258 (30.2) | |
| 9/10 MMUD | 1 (2.2) | 79 (9.2) | |
| Haploidentical | 16 (35.6) | 207 (24.2) | |
| Cumulative incidence of GVHD | |||
| 2-y moderate/severe cGVHD | 14.0 (5.6-26.2) | 6.2 (4.6-8.0) | .089 |
| Relapse | 5 (11.1) | 259 (30.3) | .798 |
| Dead | 15 (33.3) | 301 (35.2) | .006 |
| Death due to NRM | 10 (22.2) | 105 (12.3) | .001 |
| Directly secondary to LCE | 2 (4.4) | N/A |
Patients included in the analysis: patients alive at day +100 and without having presented ECEs. LCE were accounted only if occurred before presenting disease relapse.
BMI, body mass index; ECG, electrocardiogram; ECHO, echocardiography; HCT-CI, HCT–comorbidity index; MMUD, mismatched unrelated donor; MSD, matched sibling donor; MUD, matched unrelated donor; TBI, total body irradiation.
Pericarditis or moderate/severe pericardial effusion.
Patients without cardiac history but with relevant abnormalities diagnosed in the ECHO or ECG and LVEF of <5% and without a history of cardiac disorders